Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update


SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2024, and provided a general business update.

See the original post here:
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Related Posts